-
GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development
•
GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow UK biotechnology firm Ochre Bio, announcing this week that it will pay up to USD 37.5 million for access to Ochre Bio’s human liver data. This strategic collaboration aims to bolster the development of hepatology…
